<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170388</url>
  </required_header>
  <id_info>
    <org_study_id>V01-126A-201</org_study_id>
    <nct_id>NCT03170388</nct_id>
  </id_info>
  <brief_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group,&#xD;
      Clinical Study in the Treatment of Acne Vulgaris&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group,&#xD;
      Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne&#xD;
      Vulgaris&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Actual">April 23, 2019</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Lesion Counts</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Absolute change from Baseline to Week 12 in mean inflammatory lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inflammatory Lesion Counts</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Success on the Evaluator's Global Severity Score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count Changes at Week 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, 8</time_frame>
    <description>Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory Lesion Count Changes at Week 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, 8</time_frame>
    <description>Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, 8</time_frame>
    <description>Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, 8</time_frame>
    <description>Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, and 8</time_frame>
    <description>Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8</measure>
    <time_frame>Baseline to Week 2, 4, and 8</time_frame>
    <description>Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">741</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>IDP-126 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-126 Component A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Component A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-126 Component B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Component B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-126 Component C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Component C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-126 Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-126 Gel</intervention_name>
    <description>Gel</description>
    <arm_group_label>IDP-126 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-126 Component A</intervention_name>
    <description>Component A</description>
    <arm_group_label>IDP-126 Component A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-126 Component B</intervention_name>
    <description>Component B</description>
    <arm_group_label>IDP-126 Component B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-126 Component C</intervention_name>
    <description>Component C</description>
    <arm_group_label>IDP-126 Component C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-126 Vehicle Gel</intervention_name>
    <description>Vehicle Gel</description>
    <arm_group_label>IDP-126 Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female at least 9 years of age and older.&#xD;
&#xD;
          2. Written and verbal informed consent must be obtained. Subjects less than age of&#xD;
             consent must sign an assent for the study and a parent or a legal guardian must sign&#xD;
             the informed consent (if subject reaches age of consent during the study they should&#xD;
             be re-consented at the next study visit).&#xD;
&#xD;
          3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.&#xD;
&#xD;
          4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count&#xD;
             no less than 20, but no more than 100.&#xD;
&#xD;
          5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count&#xD;
             no less than 30, but no more than 150.&#xD;
&#xD;
          6. Subjects with 2 or fewer facial nodules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of an investigational drug or device within 30 days of enrollment or participation&#xD;
             in a research study concurrent with this study.&#xD;
&#xD;
          2. Any dermatological conditions on the face that could interfere with clinical&#xD;
             evaluations such as acne conglobata, acne fulminans, secondary acne, perioral&#xD;
             dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis,&#xD;
             eczema.&#xD;
&#xD;
          3. Any underlying disease(s) or some other dermatological condition of the face that&#xD;
             requires the use of interfering topical or systemic therapy or makes evaluations and&#xD;
             lesion count inconclusive.&#xD;
&#xD;
          4. Subjects with a facial beard or mustache that could interfere with the study&#xD;
             assessments.&#xD;
&#xD;
          5. Subjects with more than 2 facial nodules.&#xD;
&#xD;
          6. Evidence or history of cosmetic-related acne.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 13</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 12</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 15</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 14</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 16</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 17</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 18</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 19</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>valeant Site 21</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 20</name>
      <address>
        <city>Needham</city>
        <state>Massachusetts</state>
        <zip>02492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 22</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 24</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 25</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 27</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 26</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 23</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 28</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 30</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 31</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 32</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 33</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>valeant Site 34</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 35</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <results_first_submitted>September 17, 2021</results_first_submitted>
  <results_first_submitted_qc>October 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2021</results_first_posted>
  <disposition_first_submitted>October 21, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 10, 2021</disposition_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03170388/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IDP-126 Gel</title>
          <description>Gel&#xD;
IDP-126 Gel: Gel</description>
        </group>
        <group group_id="P2">
          <title>IDP-126 Component A</title>
          <description>Component A&#xD;
IDP-126 Component A: Component A</description>
        </group>
        <group group_id="P3">
          <title>IDP-126 Component B</title>
          <description>Component B&#xD;
IDP-126 Component B: Component B</description>
        </group>
        <group group_id="P4">
          <title>IDP-126 Component C</title>
          <description>Component C&#xD;
IDP-126 Component C: Component C</description>
        </group>
        <group group_id="P5">
          <title>IDP-126 Vehicle Gel</title>
          <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="150"/>
                <participants group_id="P5" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="132"/>
                <participants group_id="P5" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
      <group_list>
        <group group_id="B1">
          <title>IDP-126 Gel</title>
          <description>Gel&#xD;
IDP-126 Gel: Gel</description>
        </group>
        <group group_id="B2">
          <title>IDP-126 Component A</title>
          <description>Component A&#xD;
IDP-126 Component A: Component A</description>
        </group>
        <group group_id="B3">
          <title>IDP-126 Component B</title>
          <description>Component B&#xD;
IDP-126 Component B: Component B</description>
        </group>
        <group group_id="B4">
          <title>IDP-126 Component C</title>
          <description>Component C&#xD;
IDP-126 Component C: Component C</description>
        </group>
        <group group_id="B5">
          <title>IDP-126 Vehicle Gel</title>
          <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="146"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="146"/>
            <count group_id="B4" value="150"/>
            <count group_id="B5" value="148"/>
            <count group_id="B6" value="740"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="11" upper_limit="46"/>
                    <measurement group_id="B2" value="17" lower_limit="10" upper_limit="60"/>
                    <measurement group_id="B3" value="17" lower_limit="10" upper_limit="45"/>
                    <measurement group_id="B4" value="17" lower_limit="11" upper_limit="50"/>
                    <measurement group_id="B5" value="17" lower_limit="11" upper_limit="47"/>
                    <measurement group_id="B6" value="17" lower_limit="10" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="95"/>
                    <measurement group_id="B6" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Evaluator's Global Severity Score</title>
          <description>The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="127"/>
                    <measurement group_id="B6" value="623"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Lesion Counts</title>
        <description>Absolute change from Baseline to Week 12 in mean inflammatory lesion counts</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Counts</title>
          <description>Absolute change from Baseline to Week 12 in mean inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="11.86"/>
                    <measurement group_id="O2" value="-26.7" spread="11.74"/>
                    <measurement group_id="O3" value="-24.8" spread="11.71"/>
                    <measurement group_id="O4" value="-26.8" spread="11.69"/>
                    <measurement group_id="O5" value="-19.6" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-inflammatory Lesion Counts</title>
        <description>Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inflammatory Lesion Counts</title>
          <description>Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.5" spread="16.25"/>
                    <measurement group_id="O2" value="-29.9" spread="16.40"/>
                    <measurement group_id="O3" value="-27.8" spread="15.97"/>
                    <measurement group_id="O4" value="-30.0" spread="16.40"/>
                    <measurement group_id="O5" value="-21.8" spread="16.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Success on the Evaluator's Global Severity Score</title>
        <description>Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Success on the Evaluator's Global Severity Score</title>
          <description>Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="30.5"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Lesion Count Changes at Week 2, 4, and 8</title>
        <description>Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
        <time_frame>Baseline to Week 2, 4, 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Count Changes at Week 2, 4, and 8</title>
          <description>Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="11.62"/>
                    <measurement group_id="O2" value="-11.8" spread="10.80"/>
                    <measurement group_id="O3" value="-13.8" spread="10.50"/>
                    <measurement group_id="O4" value="-13.4" spread="10.76"/>
                    <measurement group_id="O5" value="-9.2" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="10.33"/>
                    <measurement group_id="O2" value="-17.1" spread="12.07"/>
                    <measurement group_id="O3" value="-18.8" spread="12.05"/>
                    <measurement group_id="O4" value="-17.7" spread="11.49"/>
                    <measurement group_id="O5" value="-14.8" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" spread="11.97"/>
                    <measurement group_id="O2" value="-23.0" spread="11.69"/>
                    <measurement group_id="O3" value="-23.1" spread="13.95"/>
                    <measurement group_id="O4" value="-22.8" spread="9.86"/>
                    <measurement group_id="O5" value="-17.5" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inflammatory Lesion Count Changes at Week 2, 4, and 8</title>
        <description>Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
        <time_frame>Baseline to Week 2, 4, 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inflammatory Lesion Count Changes at Week 2, 4, and 8</title>
          <description>Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="12.90"/>
                    <measurement group_id="O2" value="-11.0" spread="14.31"/>
                    <measurement group_id="O3" value="-11.2" spread="10.97"/>
                    <measurement group_id="O4" value="-11.3" spread="14.02"/>
                    <measurement group_id="O5" value="-9.2" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" spread="14.33"/>
                    <measurement group_id="O2" value="-18.6" spread="13.74"/>
                    <measurement group_id="O3" value="-15.8" spread="13.77"/>
                    <measurement group_id="O4" value="-18.0" spread="14.35"/>
                    <measurement group_id="O5" value="-13.7" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" spread="15.95"/>
                    <measurement group_id="O2" value="-25.1" spread="15.43"/>
                    <measurement group_id="O3" value="-21.7" spread="16.08"/>
                    <measurement group_id="O4" value="-26.8" spread="14.68"/>
                    <measurement group_id="O5" value="-17.6" spread="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</title>
        <description>Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
        <time_frame>Baseline to Week 2, 4, 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</title>
          <description>Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.89" spread="29.073"/>
                    <measurement group_id="O2" value="-30.27" spread="26.417"/>
                    <measurement group_id="O3" value="-35.10" spread="26.442"/>
                    <measurement group_id="O4" value="-35.23" spread="26.926"/>
                    <measurement group_id="O5" value="-24.18" spread="26.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.42" spread="22.683"/>
                    <measurement group_id="O2" value="-44.37" spread="28.511"/>
                    <measurement group_id="O3" value="-47.55" spread="28.040"/>
                    <measurement group_id="O4" value="-46.32" spread="27.664"/>
                    <measurement group_id="O5" value="-39.95" spread="27.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.07" spread="22.239"/>
                    <measurement group_id="O2" value="-59.07" spread="25.573"/>
                    <measurement group_id="O3" value="-59.55" spread="31.990"/>
                    <measurement group_id="O4" value="-60.10" spread="23.863"/>
                    <measurement group_id="O5" value="-46.61" spread="27.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</title>
        <description>Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
        <time_frame>Baseline to Week 2, 4, 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8</title>
          <description>Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.07" spread="26.440"/>
                    <measurement group_id="O2" value="-23.39" spread="30.433"/>
                    <measurement group_id="O3" value="-23.72" spread="22.845"/>
                    <measurement group_id="O4" value="-24.91" spread="28.698"/>
                    <measurement group_id="O5" value="-19.68" spread="23.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.17" spread="27.162"/>
                    <measurement group_id="O2" value="-39.28" spread="26.422"/>
                    <measurement group_id="O3" value="-33.84" spread="29.592"/>
                    <measurement group_id="O4" value="-38.14" spread="27.765"/>
                    <measurement group_id="O5" value="-29.53" spread="26.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.05" spread="25.164"/>
                    <measurement group_id="O2" value="-52.76" spread="27.916"/>
                    <measurement group_id="O3" value="-47.29" spread="32.982"/>
                    <measurement group_id="O4" value="-54.17" spread="26.530"/>
                    <measurement group_id="O5" value="-37.84" spread="29.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8</title>
        <description>Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
        <time_frame>Baseline to Week 2, 4, and 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8</title>
          <description>Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49"/>
                    <measurement group_id="O2" value="1.35"/>
                    <measurement group_id="O3" value="0.71"/>
                    <measurement group_id="O4" value="2.68"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17"/>
                    <measurement group_id="O2" value="6.77"/>
                    <measurement group_id="O3" value="2.79"/>
                    <measurement group_id="O4" value="4.27"/>
                    <measurement group_id="O5" value="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.46"/>
                    <measurement group_id="O2" value="15.97"/>
                    <measurement group_id="O3" value="15.26"/>
                    <measurement group_id="O4" value="15.75"/>
                    <measurement group_id="O5" value="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8</title>
        <description>Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
        <time_frame>Baseline to Week 2, 4, and 8</time_frame>
        <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-126 Gel</title>
            <description>Gel&#xD;
IDP-126 Gel: Gel</description>
          </group>
          <group group_id="O2">
            <title>IDP-126 Component A</title>
            <description>Component A&#xD;
IDP-126 Component A: Component A</description>
          </group>
          <group group_id="O3">
            <title>IDP-126 Component B</title>
            <description>Component B&#xD;
IDP-126 Component B: Component B</description>
          </group>
          <group group_id="O4">
            <title>IDP-126 Component C</title>
            <description>Component C&#xD;
IDP-126 Component C: Component C</description>
          </group>
          <group group_id="O5">
            <title>IDP-126 Vehicle Gel</title>
            <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8</title>
          <description>Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.</description>
          <population>One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95"/>
                    <measurement group_id="O2" value="2.78"/>
                    <measurement group_id="O3" value="1.45"/>
                    <measurement group_id="O4" value="5.44"/>
                    <measurement group_id="O5" value="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46"/>
                    <measurement group_id="O2" value="10.53"/>
                    <measurement group_id="O3" value="5.83"/>
                    <measurement group_id="O4" value="8.51"/>
                    <measurement group_id="O5" value="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.74"/>
                    <measurement group_id="O2" value="22.79"/>
                    <measurement group_id="O3" value="19.97"/>
                    <measurement group_id="O4" value="20.66"/>
                    <measurement group_id="O5" value="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>There were 6 IDP-126, 4 Component A, 2 Component B, 2 Component C, and 2 Vehicle participants excluded from the adverse event analysis since they did not have post-baseline safety evaluations.</desc>
      <group_list>
        <group group_id="E1">
          <title>IDP-126 Gel</title>
          <description>Gel&#xD;
IDP-126 Gel: Gel</description>
        </group>
        <group group_id="E2">
          <title>IDP-126 Component A</title>
          <description>Component A&#xD;
IDP-126 Component A: Component A</description>
        </group>
        <group group_id="E3">
          <title>IDP-126 Component B</title>
          <description>Component B&#xD;
IDP-126 Component B: Component B</description>
        </group>
        <group group_id="E4">
          <title>IDP-126 Component C</title>
          <description>Component C&#xD;
IDP-126 Component C: Component C</description>
        </group>
        <group group_id="E5">
          <title>IDP-126 Vehicle Gel</title>
          <description>Vehicle Gel&#xD;
IDP-126 Vehicle Gel: Vehicle Gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact sponsor for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health Americas, Inc</organization>
      <phone>5102595284</phone>
      <email>aloncaric@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

